Attēls:Different approaches for the development of vaccine candidates against SARS‐Cov‐2.png
Sākotnējais fails (3 191 × 3 917 pikseļi, faila izmērs: 2,15 MB, MIME tips: image/png)
 | Šis fails ir no Vikikrātuves. Tā apraksts no attēla lapas Vikikrātuvē ir parādīts zemāk. Vikikrātuve ir brīvi licencēta failu krātuve. Tu vari tai palīdzēt. |
Kopsavilkums
| Apraksts |
English: Different approaches for the development of vaccine candidates against SARS‐Cov‐2.
Different approaches for the development of vaccine candidates against SARS‐Cov‐2. (A) Potential vaccines under development involve five leading platforms (inactivated virus, protein subunit, DNA, RNA, and non‐replicating viral vector), as depicted. (B) Intact SARS‐CoV‐2 is neutralized by treatment with radiation to cease its ability to infect and replicate, while preserving the induction of an immune response. (C) A plasmid DNA is genetically engineered with the S, M, and N genes of SARS‐CoV‐2 encoding the respective proteins that may facilitate an immune response. (D) A replication‐defective Adenovirus (Ad) vector is genetically engineered to express SARS‐Cov‐2 spike (S) protein. (E) An mRNA (replication‐defective) that encodes the S protein of SARS‐CoV‐2 is encapsulated in a lipid nanoparticle (LNP), which, when injected, induces the body cells to produce the spike protein and direct the immune response. (F) Spike protein‐encoding (S) gene of SARS‐CoV‐2 was isolated and genetically engineered into a baker’s yeast, producing the spike protein antigens when grown. The produced S antigens can then be collected and purified. |
| Datums | |
| Avots |
Mathew, S.; Faheem, M.; Hassain, N.A.; Benslimane, F.M.; Thani, A.A.A.; Zaraket, H.; Yassine, H.M. Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines 2021, 9, 11. https://doi.org/10.3390/vaccines9010011 |
| Autors | Mathew, S.; Faheem, M.; Hassain, N.A.; Benslimane, F.M.; Thani, A.A.A.; Zaraket, H.; Yassine, H.M. |
|
This biology image could be re-created using vector graphics as an SVG file. This has several advantages; see Commons:Media for cleanup for more information. If an SVG form of this image is available, please upload it and afterwards replace this template with
{{vector version available|new image name}}.
It is recommended to name the SVG file “Different approaches for the development of vaccine candidates against SARS‐Cov‐2.svg”—then the template Vector version available (or Vva) does not need the new image name parameter. |
Licence
- Jūs varat brīvi:
- koplietot – kopēt, izplatīt un pārraidīt darbu
- remiksēt – pielāgot darbu
- Saskaņā ar šādiem nosacījumiem:
- atsaucoties – Tev ir jānorāda autors, saite uz licenci un to, vai veiktas kādas izmaiņas. To var darīt jebkādā saprātīgā veidā, bet ne tādā, kas norādītu, ka licencētājs atbalsta tevi vai veidu, kā tu izmanto šo darbu.
Faila hronoloģija
Uzklikšķini uz datums/laiks kolonnā esošās saites, lai apskatītos, kā šis fails izskatījās tad.
| Datums/Laiks | Attēls | Izmēri | Dalībnieks | Komentārs | |
|---|---|---|---|---|---|
| tagadējais | 2020. gada 31. decembris, plkst. 17.50 | | 3 191 × 3 917 (2,15 MB) | Balkanique | better quality |
| 2020. gada 25. decembris, plkst. 20.41 |  | 1 327 × 1 495 (858 KB) | Balkanique | Cropped 33 % horizontally, 42 % vertically using CropTool with lossless mode. | |
| 2020. gada 25. decembris, plkst. 20.38 |  | 1 989 × 2 574 (885 KB) | Balkanique | Uploaded a work by Mathew, S.; Faheem, M.; Hassain, N.A.; Benslimane, F.M.; Thani, A.A.A.; Zaraket, H.; Yassine, H.M. from Mathew, S.; Faheem, M.; Hassain, N.A.; Benslimane, F.M.; Thani, A.A.A.; Zaraket, H.; Yassine, H.M. Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines 2021, 9, 11. with UploadWizard |
Faila lietojums
Šo failu izmanto šajā 1 lapā:
Globālais faila lietojums
Šīs Vikipēdijas izmanto šo failu:
- Izmantojums hu.wikipedia.org
